Acorda

November 20, 2017November 20, 2017

Fampyra/Ampyra May Improve Walking Speed in MS Patients Over Longer Term, Study Says

News

Available long-term data on Fampyra (fampridine; 4-aminopyridine) suggest the treatment may improve walking speed in patients with multiple sclerosis (MS) for up to one year, but more research ... Read more

September 14, 2017September 13, 2017

There’s an App (Maybe Too Many) for That!

Columns, Engaging Thoughts

How many hours do the pharmaceutical companies think we have in our day? I ask because almost all of them have come up with very slick ... Read more

July 11, 2017July 17, 2017

Long-term Use of Ampyra Lowers Medical Costs, Hospital Visits for MS Patients, Study Finds

News

A recent study has found that continued use of Ampyra (dalfampridine extended-release, sold in the U.S. by Acorda Therapeutics) by patients with multiple sclerosis (MS) lowers ... Read more

April 4, 2017April 12, 2017

Ampyra: A Generic for the MS ‘Walking Drug’ Wins a Round in Court

Columns, The MS Wire - A Column by Ed Tobias

Ampyra is marketed as the only multiple sclerosis (MS) drug that is designed to increase an MS patient’s walking speed. Clinical studies show that patients who ... Read more

Pin It on Pinterest